NFE2 and myeloproliferative disorder: Guglielmelli et al. reported that NF-E2 mutations were twofold more frequent among 631 MPN patients who had JAK2 VAF > 50%, however, there were no clear prognostic or meaningful clinical/hematological correlates [116].